Camilla Jandus awarded Swiss National Science Foundation PRIMA grantResearch into the manipulation of the innate immune system to optimise cancer immunotherapy
Dr Jandus' group is interested in a recently described family of rare, but potent cytokine secreting cells, called Innate Lymphoid Cells (ILCs), that is emerging as key regulator of immunity. The team have been pioneering in identifying novel, dominant ILC2-dependent circuits of immunosuppression in cancer.
The Swiss National Science Foundation (SNSF) PRIMA funding will support the decoding of the transcriptional and epigenetic immunosuppressive ILC2-signatures established in the tumor microenvironment in patients. By therapeutically interfering with the identified circuits in preclinical mouse models, the impact of the C.Jandus lab's discoveries will be explored directly in vivo, in view of phase I clinical trials.
Through its PRIMA grant programme, the SNSF aims to support outstanding women researchers who show a high potential for obtaining a professorship. Camilla Jandus is one of 22 female academics chosen, from 189 applicants .